There are two caveats to this approach: first, AR expression is used as a biomarker for patient selection but AR-FL activity markedly varies depending on ERα status and molecular subtype [4]; and second, ADT in men inevitably leads to therapy resistant, lethal disease, but whether such treatment-associated selection pressure will occur in breast cancer is unknown. The gene discussed is AR; the disease is breast cancer.